dextromethorphan hydrobromide, bupropion hydrochloride

FDA Drug Profile — AUVELITY

dextromethorphan hydrobromide, bupropion hydrochloride is listed in the FDA National Drug Code directory with 7 NDC codes, marketed under brand name including AUVELITY. Available dosage forms: tablet, multilayer, extended release, kit.

Drug details

Generic Name
dextromethorphan hydrobromide, bupropion hydrochloride
Brand Names
AUVELITY
Application Number
NDA215430
Sponsor
Axsome Therapeutics, Inc.
NDC Codes
7
Dosage Forms
TABLET, MULTILAYER, EXTENDED RELEASE, KIT
Routes
ORAL
Active Ingredients
DEXTROMETHORPHAN HYDROBROMIDE, BUPROPION HYDROCHLORIDE

Indications and Usage

1 INDICATIONS AND USAGE AUVELITY is a combination of dextromethorphan, an uncompetitive N -methyl D -aspartate (NMDA) receptor antagonist and sigma-1 receptor agonist, and bupropion, an aminoketone and CYP450 2D6 inhibitor, indicated for the treatment of major depressive disorder (MDD) in adults ( 1.1 ) the treatment of agitation associated with dementia due to Alzheimer’s disease ( 1.2 ) Limitations of Use: AUVELITY is not indicated as an as needed (“prn”) treatment for agitation associated with dementia due to Alzheimer’s disease (1.2). 1.1 Major Depressive Disorder AUVELITY is indicated for the treatment of major depressive disorder (MDD) in adults. 1.2 Agitation Associated with Dementia Due to Alzheimer’s Disease AUVELITY is indicated for the treatment of agitation associated with dementia due to Alzheimer’s disease. Limitations of Use: AUVELITY is not indicated as an as needed (“prn”) treatment for agitation associated with dementia due to Alzheimer’s disease [see Clinical Studies Section 14.2 ].

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.